Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | MultiTAA-specific T cells |
| Trade Name | |
| Synonyms | TAA-CTL|TAA-T|TAA-specific CTLs |
| Drug Descriptions |
MultiTAA-specific T cells are T-lymphocytes that have been treated with dendritic cells exposed to a cocktail of tumor-associated antigens (TAAs) such as WT1, PRAME, NY-ESO1, MAGEA4 and Survivin, which have potential antitumor activity against tumors expressing TAAs (Blood (2015) 126 (23): 186; Blood (2017) 130 (Supplement 1): 164). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Azacitidine + MultiTAA-specific T cells | Azacitidine MultiTAA-specific T cells | 0 | 1 |
| Azacitidine + MultiTAA-specific T cells + Ondansetron | Azacitidine MultiTAA-specific T cells Ondansetron | 0 | 0 |
| MultiTAA-specific T cells | MultiTAA-specific T cells | 0 | 10 |
| MultiTAA-specific T cells + Nivolumab | MultiTAA-specific T cells Nivolumab | 0 | 1 |